COMMUNIQUÉS West-GlobeNewswire

Notice to convene Annual General Meeting 2019 of GN Store Nord
27/02/2019
Please find enclosed notice of GN Store Nord A/S’ Annual General Meeting 2019, including the complete proposals for the agenda For further information, please contact: Investors and analysts Peter Justesen VP – Investor [...]
Progressive Care Inc. Subsidiary PharmCo, LLC Earns Top Performance Scores From Humana Inc.
27/02/2019
MIAMI, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ), a personalized healthcare services and technology company, today announced that its wholly owned subsidiary PharmCo, LLC has met all three [...]
Milestone Scientific’s Director of Clinical Affairs Interviewed on Proactiveinvestors.com
27/02/2019
LIVINGSTON, N.J., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug instruments that provide painless and precise injections, today announced that Dr. [...]
Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to 1 Year
27/02/2019
Long Term Data on FMX103 Demonstrated a Generally Favorable Safety Profile; 81.6% of Patients Achieved Clear or Almost Clear Skin at 52 Weeks REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 27, 2019 (GLOBE NEWSWIRE) -- [...]
Allogene Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 8, 2019
27/02/2019
Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company [...]
CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
27/02/2019
OSLO, Norway, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines, have announced a [...]
Strongbridge Biopharma plc to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference
27/02/2019
DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
Michigan: A Lucrative Cannabis Market with Tight Regulations -- CFN Media
27/02/2019
SEATTLE, Feb. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
Sarepta Exercises Option to Acquire Myonexus Therapeutics
27/02/2019
-- Exercise Fee is $165 Million -- -- Sarepta to Acquire Myonexus’ Portfolio of Five Gene Therapy Candidates to Treat Distinct Forms of Limb-Girdle Muscular Dystrophy (LGMD) -- CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE [...]
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
27/02/2019
NEW YORK, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
27/02/2019
- On track for clinical data update from trials in multiple solid tumors at the Q1 2019 earnings update call in May - - Completed initial safety cohorts for ADP-A2M10 (MAGE-A10) in lung and triple tumor studies as well [...]
Resonant to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Thursday, March 14th at 1:30 p.m. Pacific Daylight Time
27/02/2019
GOLETA, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ:RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices [...]
Clearside Biomedical to Report 2018 Financial Results and Provide Corporate Update on Tuesday, March 12, 2019
27/02/2019
ALPHARETTA, Ga., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Medtronic Announces FDA Clearance and U.S. Launch of the Accurian Radio Frequency System for Nerve Tissue Ablation
27/02/2019
Medtronic Expands Pain Portfolio with Minimally Invasive Therapy to Support Patients Throughout the Care Continuum DUBLIN - February 27, 2019 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration [...]
Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019
27/02/2019
Conference Call and Webcast Scheduled for Wednesday, March 6 at 8:00 a.m. Eastern Time YARDLEY, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear [...]
Terranueva Raises $278,750 Following Exercise of Rights
27/02/2019
MONTREAL, Feb. 27, 2019 (GLOBE NEWSWIRE) -- TERRANUEVA CORPORATION (“Terranueva”) (CSE: TEQ) announces that it has raised $278,743.04 from its rights offering (the “Rights”), which started on October 30, 2018, while [...]
Terranueva amasse 278 750 $ suite à l’exercice de droits
27/02/2019
MONTRÉAL, 27 févr. 2019 (GLOBE NEWSWIRE) -- CORPORATION TERRANUEVA (« Terranueva » ou la « Société ») (CSE: TEQ) annonce avoir amassé 278 743,04 $ suite à la conclusion de son placement de droits (les « Droits »), ayant [...]
G1 Therapeutics to Host Investor Day 2019 on March 6, 2019
27/02/2019
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host its Investor Day 2019 on Wednesday, March 6 in [...]
Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
27/02/2019
- Results from the Phase 2 Expansion of ILLUMINATE-204 anticipated to be reported in the 4 th Quarter of 2019 – - December 2018 Interim Update of 34 efficacy evaluable patients demonstrated 32.4% achieved partial [...]

Pages